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Systemic sclerosis (SSc) is characterized by chronic inflammation and fibrosis. N-Formyl peptide (fMLF) receptors (FPRs) are
chemotactic receptors involved in inflammation. Three FPRs have been identified: FPR1, FPR2, and FPR3. We have examined, by
RT-PCR, Western blot and immunohistochemistry, FPRs expression in skin fibroblasts from 10 normal subjects and 10 SSc
patients, showing increased expression in SSc fibroblasts. Several functions of FPRs occur through the interaction with a region of
the urokinase-type plasminogen activator receptor (uPAR88–92), able to interact with FPRs and to mediate urokinase (uPA) or
fMLF-dependent cell migration. Soluble uPAR84–95 peptide can act as a direct ligand of FPRs. Furthermore, uPA or its amino-
terminal fragment (ATF) can promote the exposure of the uPAR88–92 region. The WKYMVm peptide is a FPRs pan-agonist. We
investigated the functional effects of these agonists on normal and SSc fibroblasts. ATF, uPAR84–95, and WKYMVm regulated
adhesion, migration, and proliferation of normal fibroblasts. Despite FPR overexpression, the response of SSc fibroblasts to the
same agonists was greatly reduced, except for the proliferative response to ATF. SSc fibroblasts showed increased a-smooth
muscle actin expression and improved capability to induce wound closure. Indeed, they overexpressed a cleaved uPAR form,
exposing the uPAR88–92 region, and vitronectin, both involved in fibrosis and in the fibroblast-to-myofibroblast transition. FPR
stimulation promoted a-smooth muscle actin expression in normal fibroblasts as well as motility, matrix deposition, avb5 integrin
expression, and radical oxygen species generation in normal and SSc fibroblasts. This study provides evidence that FPRs may play
a role in fibrosis and in the fibroblast-to-myofibroblast transition. The Journal of Immunology, 2015, 194: 5161–5173.
S
ystemic sclerosis (SSc) is a chronic systemic disease
characterized by impaired communication between endo-
thelial cells, epithelial cells and fibroblasts, lymphocyte
activation, autoantibody production, inflammation, and connective
tissue fibrosis (1). The pathogenesis of SSc is extremely complex.
and despite a number of studies that examined several aspects
of its intricate picture, the mechanisms involved are still largely
unknown. During the past decade, considerable attention has been
paid to the origin of myofibroblast, the mesenchymal cell type
most responsible for the excessive matrix production and depo-
sition in tissue and vessel wall, found in fibrotic disorders and
fibroproliferative vasculopathies (2). However, in SSc, the origin
of myofibroblasts has not been completely elucidated (3). In fi-
brotic diseases, myofibroblasts may derive from at least three
sources: 1) expansion and activation of resident tissue fibroblasts;
2) transition of epithelial cells into mesenchymal cells, a process
known as epithelial–mesenchymal transition; and 3) tissue mi-
gration of bone marrow–derived circulating fibrocytes (4). Under
normal circumstances, the fibroblast repair program is self limited,
but pathological fibrotic responses are characterized by sustained
and amplified fibroblast activation (5).
In SSc, inappropriate fibroblast activation and subsequent ac-
cumulation of myofibroblasts in affected tissues and the persistence
of their elevated biosynthetic functions are crucial determinants of
the extent and rate of fibrosis and influence significantly also the
clinical course of the disease as well as the response to therapy, thus
dictating the prognosis and the overall mortality (6). Recently,
endothelial mesenchymal transition (EndoMT), a newly recog-
nized type of cellular transdifferentiation, has emerged as another
possible source of tissue myofibroblasts, deeply involved in the
pathogenesis of fibrotic diseases (7).
EndoMT is a complex biological process in which endothelial
cells lose their specific endothelial cell markers, such as vascular
endothelial cadherin. Consequently, fibroblasts acquire a mesen-
chymal or myofibroblast phenotype, expressing its typical markers,
such as a-smooth muscle actin (a-SMA), vimentin, and types I
and III interstitial collagens. Besides the acquisition of an acti-
vated profibrogenic phenotype, these cells also become motile and
capable of migrating into surrounding tissues (8). Today, the
EndoMT process is gaining increased attention in fibrotic dis-
orders, although only few experimental evidences support the
participation of EndoMT in the pathogenesis of SSc (8).
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Moreover, the origin of myofibroblasts in SSc may also include
pericyte cells (9). Small blood vessels make up two cell types:
endothelial cells and pericytes. Microvascular pericytes are in
intimate contact with, and modulate the function of, endothelial
cells. In SSc, such pericytes may contribute to the overproduction
of extracellular matrix (ECM) molecules and constitute a cellular
link between microvascular damage and fibrosis by transdiffer-
entiating into myofibroblasts (10).
The N-formyl peptide receptor (FPR) family is a group of cell
surface receptors acting as pattern recognition receptors, regulat-
ing many cellular activities, such as migration, proliferation,
differentiation, growth, and death. Their involvement in innate
inflammatory responses is well established (11). Three FPRs have
been identified in humans, namely FPR1, FPR2, and FPR3 (12).
FPRs, by interacting with several structurally diverse pro- and
anti-inflammatory ligands, seem to possess important regulatory
effects in multiple pathological conditions, including inflamma-
tion, amyloidosis, Alzheimer’s disease, prion disease, AIDS, obe-
sity, diabetes, and cancer (13). FPR1 is activated by nanomolar
concentrations of fMet-Leu-Phe (fMLF), a potent leukocyte che-
moattractant (11). FPR2 is a promiscuous receptor activated in
response to high concentration of fMLF, viral, bacterial, endoge-
nous, and synthetic peptides (12). Hp(2–20) (14), and F2L (15) are
natural ligands for FPR3. The synthetic peptide WKYMVm (11)
is an FPR panagonist. All FRRs expressed on epithelia seem to be
required for wound repair and restitution of barrier integrity. In
this regard, we have recently demonstrated that FPRs activation
facilitates epithelial cell migration, proliferation, and neoangio-
genesis in gastric and nasal epithelial cells (16, 17).
One regulator of the signal transduction pathways, involved in
both epithelial mesenchymal transition (18) and EndoMT (19), is
the urokinase-type plasminogen activator (uPA)–uPA receptor
(uPAR) system. uPAR is formed by three homologous domains
(DI, DII, and DIII) anchored to the cell surface by a GPI tail (20).
The main uPAR activity is the focusing of proteolytic uPA activity
on the cell membrane (21). uPA is a serine protease that activates
plasminogen to plasmin; uPA or its aminoterminal fragment
(ATF), devoid of enzymatic activity, binds uPAR with high
specificity and affinity (22). However, uPAR has also been re-
ported to be a major protein involved in other events such as
wound repair, tumor progression, angiogenesis, by interacting
with integrins, FPRs, and tyrosine kinase receptors (23).
In addition, uPAR binds vitronectin, which has been reported to
be an extracellular matrix protein that develops in response to tissue
injury, especially in the early provisional matrix (24) involved
in liver and lung disease, where its expression is closely associ-
ated with fibrosis (25). Vitronectin, also known as S protein of
the complement regulatory pathway, has been demonstrated by
in vitro studies to bind cellular receptors including the integrins
avb3 and avb5, which are also uPAR coreceptors (18).
FPR interaction with uPAR mediates uPA-dependent cell mi-
gration and is required for chemotaxis induced by fMLF (26). A
specific site corresponding to aa 88–92 (SRSRY), located in the
flexible linker connecting the uPAR domains DI and DII, is re-
sponsible of uPAR cross-talk with FPRs (27). In fact, the soluble
uPAR84–95 peptide can promote directional cell migration by
binding to FPRs, thus representing an endogenous ligand of FPRs
(27). Exposure of uPAR84–92 region on the cell membrane is fa-
vored by uPAR cleavage (26) or by uPA binding to uPAR (28).
Previously, we focused our attention on the urokinase-mediated
plasminogen activation (PA) system in skin fibroblasts of SSc,
highlighting a role of uPA and uPAR in the disease (29). Fur-
thermore, it has been demonstrated that, in SSc, uPAR repre-
sents a critical effector molecule also in endothelial cells,
contributing to their migration and differentiation. Indeed, in
microvascular endothelial cells of diffuse SSc, uPAR cleavage
operated by overexpressed matrix metalloproteinase-12 con-
tributes to the impaired angiogenesis observed both in vitro and
in SSc patients (30).
To test the possibility that fibroblast FPRs are involved in the
pathogenesis of SSc and that uPAR–FPR interaction may be
crucial, in particular, in the fibroblast-to-myofibroblast transition,
we investigated whether FPRs are expressed on human skin
fibroblasts of patients affected by different grade of SSc and
whether their activation plays a role in some as yet unexplained
mechanisms involved in SSc, such as wound healing, tissue
remodeling, and fibrosis.
To our knowledge, we provide, for the first time, evidence of
FPR overexpression in human skin SSc fibroblasts, both in vivo
and in vitro. We also show that their activation through specific
agonists may contribute to a myofibroblast phenotype of SSc
fibroblasts because FPRs stimulation is able to increase a-SMA
expression in normal skin fibroblasts as well as avb5 integrin
expression, ECM deposition, and reactive oxygen species (ROS)
production in both normal and SSc fibroblasts. Taken together, all
our observations emphasize the intriguing role of these receptors
in the pathogenesis of SSc.
Materials and Methods
Peptides and chemicals
The hexapeptide Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) was
synthesized and HPLC purified (.95%) by Innovagen (Lund, Sweden), the
peptide uPAR88–92 was synthesized by PRIMM (Milan, Italy), and the
uPA N-terminal fragment (ATF-uPA) was from American Diagnostica
(Greenwich, CT).
TRIzol solution was from Invitrogen Fischer Scientific (Illkirch, France),
and DNA ladder and Moloney leukemia virus reverse transcriptase were
from Promega (Madison, WI). Protein concentration was estimated with
a modified Bradford assay (Bio-Rad Laboratories). CellTiter 96 Aqueous
One Solution Reagent was from Calbiochem (San Diego, CA), ECL Plus
was from GE Healthcare (Buckinghamshire, UK), and 29,79-dichlor-
odihydrofluorescein diacetate (DCHF-DA) was from Molecular Probes
(Invitrogen, Paisley, UK).
The mixture of protease and phosphatase inhibitors was from Calbio-
chem. Mouse anti-FPR1, rabbit anti-FPR2, mouse anti-FPR3, rabbit anti-
avb5 integrin, mouse anti-collagen type I, and mouse anti-fibronectin were
from Santa Cruz Biotechnology (Santa Cruz, CA), rabbit anti-FPR2
for immunocytochemistry mouse anti–a-SMA, mouse anti-tubulin, and
rabbit anti-actin were from Sigma-Aldrich (St. Louis, MO), mouse anti-
vitronectin was from Chemicon International (Temecula, CA), mouse
anti-uPAR84–95 was from PRIMM. Secondary anti-mouse and anti-rabbit
Abs coupled to HRP were from Bio-Rad (Munchen, Germany). For
chemotaxis assay 8-mm-pore polycarbonate membranes (Nucleopore,
Pleasanton, CA) coated with 10 mg/ml fibronectin (Roche, Mannheim,
Germany) were used. Fibronectin (Roche), collagen type I (Chemicon
International), or vitronectin (BD Biosciences, Bedford, MA) were used
for plastic coating.
Tissues and patients samples
Eight females and two males affected, observed from January 2011 to
December 2013 in the Day Hospital of the Department of Translational
Medical Sciences of the University of Naples Federico II, were classified
according to the American College of Rheumatology criteria (31) as having
limited cutaneous SSc (n = 6) or diffuse cutaneous (dcSSc; n = 4) (32) and
included in the study. All patients signed a written informed consent
according to the guidelines of the institutional review board for the use of
humans in research. The mean age of patients was 54 y (range, 31–70 y).
Disease duration was calculated from the time of onset of the first clinical
event (other than Raynaud’s phenomenon) that was a clear manifestation
of SSc. Patients were classified as having an early-stage (n = 4) or late-
stage (n = 6) SSc, according to disease duration (,5 y for early-stage
limited cutaneous SSc and ,3 y for early-stage diffuse cutaneous SSc)
and skin histopathology (33). We considered clinically involved skin for
values of skin thickness $ 2, according to the modified Rodnan skin
thickness score. All patients with the diffuse form had involvement of
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dorsal arm and/or thorax. To reduce variability among the patients, we
admitted for study only SSc patients positive for antinuclear Abs, showing
a speckled pattern as evaluated by indirect immunofluorescence and
ELISA. Because antinuclear Ab positivity may be considered not sufficient
for subtype characterization, other clinical measures were investigated; in
particular, all patients with diffuse cutaneous SSc presented anti–SCL-70
topoisomerase I positivity, and patients with limited cutaneous SSc showed
serum anticentromere (CENP-B) positivity. All patients were washed out
from steroid treatment 30 d before the biopsy was taken. Other treatments
were allowed (proton pump inhibitors, vasodilators, and so on). Patients
who could not undergo washout because of the severe organ complications
were not evaluated. Patients with symptoms overlapping with those of
other autoimmune, rheumatic, and/or connective tissue diseases were ex-
cluded from the study. Control donors were matched with each sclero-
derma patient for age, sex, and biopsy site, and control samples were
processed in parallel control (eight females and two males; mean 6 SD
age, 43 6 15 y).
Cell culture
Surgical fragments were mechanically dissociated under a light microscope
and subjected to trypsinization for 30 min at 37˚C, as described previously
(29). After two PBS washings, cells were plated and cultured in monolayer
in DMEM (Life Technologies Carlsbad, CA) supplemented with 10% heat-
inactivated FBS (Life Technologies), 100 U/ml penicillin G sodium, and
100 mg/ml streptomycin sulfate, at 37˚C, in a humidified atmosphere of 5%
CO2. Fibroblasts from normal subjects and from patients with SSc were
used between the 3rd and 10th passage in culture. The KG-1 (juman
myeloid cell line), the K-562 (human myelogenous leukemia cell line), and
the U-937 (human leukemic monocyte lymphoma cell line) were grown in
RPMI 1640 medium (Life Technologies) supplemented with 10% FBS.
The BJ (human foreskin fibroblasts) were grown in DMEM (Life Tech-
nologies) supplemented with 10% FBS.
RNA purification and analysis
Total cellular RNA was isolated by lysing cells in TRIzol solution,
according to the supplier’s protocol (28). RNA was precipitated and
quantitated by spectroscopy. Five micrograms of total RNA was reversely
transcribed with random hexamer primers and 200 U murine Moloney
leukemia virus reverse transcriptase. One microliter of reverse-transcribed
DNA was then amplified for FPR1, FPR2, FPR3, and GAPDH using
specific primers. The primers for FPR1 were 59-ATGGAGACAAATT-
CCTCTCTC (sense) and 39-CACCTCTGCAGAAGGTAAAGT (antisense)
(26); for FPR2 were 59-CTTGTGATCTGGGTGGCTGGA (sense) and 39-
CATTGCCTGTAACTCAGTCTC (antisense) (28); and for FPR3 were 59-
AGTTGCTCCACAGGAATCCA (sense) and 39-GCCAATATTGAAGT-
GGAGGATCAGA (antisense) (34). The primers for GAPDH were 59-
GCCAAAGGGTCATCATCTC (sense) and 39-GTAGAGGCAGGGATG-
ATGTTC (antisense). PCR products, together with a DNA ladder as a size
standard, were separated on a 1% agarose gel, stained with ethidium
bromide, and quantified with the image analysis system ChemiDoc
XRSn (Bio-Rad Laboratories).
Western blot analysis
Immunoblotting experiments were performed according to standard pro-
cedures (28). Briefly, cells were harvested in lysis buffer (50 mM HEPES,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM
MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, and 1 mM Na3VO4)
supplemented with a mixture of proteases and phosphatases inhibitors.
Fifty micrograms of protein was electrophoresed on a 10% SDS-PAGE and
transferred onto a polyvinylidene fluoride membrane. The membrane was
blocked with 5% nonfat dry milk and probed with specific Abs: mouse
anti-FPR1 (1 mg/ml), rabbit anti-FPR2 (1 mg/ml), mouse anti-FPR3 (1 mg/ml),
mouse anti–a-SMA (2 mg/ml), mouse anti-vitronectin (1 mg/ml), mouse
anti-uPAR84–95 (1 mg/ml), rabbit anti-avb5 integrin (1 mg/ml), mouse
anti-tubulin (0.5 mg/ml), and rabbit anti-actin (0.5 mg/ml). Finally,
washed filters were incubated with HRP-conjugated anti-rabbit or anti-
mouse Abs. The immunoreactive bands were detected by a chemilumi-
nescence kit and quantified by densitometry (ChemiDoc XRS, Bio-
Rad).
Cell adhesion assay
The adhesion assays were conducted in 96-well flat-bottom plates for cell
(Nunc). Wells were coated with 1 mg collagen type I or with 100 ml heat-
inactivated 1% BSA in PBS, as a negative control, and incubated overnight
at 4˚C. The plates were then blocked 1 h at room temperature with 1%
heat-inactivated 1% BSA in PBS. Cells were detached with PBS con-
taining 2 mM EDTA and then washed with serum-free DMEM, counted,
distributed into the wells at a density of 105 cells/well, and incubated for
1 h at 37˚C in the presence or in the absence of ATF-uPA (1028 M),
uPAR84–95 (10
29 M), and WKYMVm peptide (1029 M). Attached cells
were fixed with 3% paraformaldehyde in PBS for 10 min and then incu-
bated with 2% methanol for 10 min. Cells were finally stained for 10 min
with 0.5% crystal violet in 20% methanol. Stain was eluted by 0.1 mol/l
sodium citrate in 50% ethanol (pH 4.2), and the absorbance at 540 nm was
measured by a spectrophotometer.
Chemotaxis assay
Human skin fibroblasts chemotaxis was performed using a modified Boyden
chamber technique (35). Briefly, 25 ml of medium alone or added
with chemoattractants (ATF-uPA [1028 M], uPAR84–95 [10
29 M], and
WKYMVm peptide (1029 M)] were placed in triplicate in the lower
compartment of a 96-well microchemotaxis chamber (NeuroProbe, Cabin
John, MD). The lower compartments were covered with 8-mm-pore poly-
carbonate membranes coated with 10 mg/ml fibronectin. Fifty microliters
of the cell suspension (5 3 104/well), resuspended in medium alone, was
loaded into the upper compartments. The chemotactic chamber was then
incubated for 6 h at 37˚C in a humidified incubator with 5% CO2. Then,
the membrane was removed, the upper side was washed with PBS, and
cells were attached to the lower surface of the filter were fixed, stained
with May-Gr€unwald-Giemsa, mounted on a microscope slide with Cyto-
seal (Stephens Scientific, Springfield, NJ), and counted. In each experi-
ment, 10 fields/triplicate filter were measured at 340 magnification.
Checkerboard analyses were performed to discriminate between chemo-
taxis and nondirected migration (chemokinesis) of skin fibroblast cells. In
these experiments, cells were placed in the upper chemotactic chambers,
and various concentrations of stimuli or buffer were added to the upper or
lower wells or to both. Spontaneous migration (chemokinesis) was deter-
mined in the absence of chemoattractant or when stimuli were added to
either the lower or upper chambers. The cell migratory response to che-
motactic stimuli was largely due to chemotaxis and not to chemokinesis.
Indeed, a checkerboard analysis, in which chemoattractants above and
below the filters varied, resulted in significant migration only when there
was a gradient of the factor below the filters.
Proliferation assay
Human skin fibroblasts were serum-starved overnight using DMEM 0.1%
BSA, plated at 53 103 cells/well in 96-well plates, and incubated with cell
culture medium alone or with specific agonists (ATF-uPA [1028 M],
uPAR84–95 [10
29 M], and WKYMVm peptide [1029 M]) or with 10% FBS
for 1, 24, 48, 72 h, and 7 d at 37˚C, 5% CO2. At the end of the incubation,
20 ml/well CellTiter-96 was added. After incubation at 37˚C for 2 h, the
absorbance was determined by an ELISA reader (Bio-Rad) at a wavelength
of 490 nm.
In vitro wound healing assay
Sixty-millimeter cell culture dishes were coated with fibronectin (10mg/ml)
or 50 mg/ml poly-L-lysine, as a negative control, for 2 h at 37˚C. Coated
dishes were blocked with 3 ml of 2 mg/ml BSA for 1 h at 37˚C. Normal
and SSc fibroblast cells were plated using DMEM containing 2.5% FBS
and incubated for 6 h at 37˚C to create a confluent monolayer. Cell
monolayers were scraped with a p200 pipette tip in a straight line to create
a “scratch.” The debris was removed, and the edge of the scratch was
smoothed by washing cells once with 1 ml growth medium. Normal and
SSc fibroblasts were then incubated at 37˚C with or without specific
agonists (ATF-uPA [1028 M], uPAR84–95 [10
29 M], and WKYMVm
peptide [1029 M]) for 8 and 24 h. Images of the scratched areas were taken
at different times, in the same field, as marked by reference points close to
the scratch. The healing of the scratch, for each condition, was expressed
as a percentage of the original wound measured in three different points.
In situ ELISA
A quantitative analysis of ECM components (fibronectin, collagen type I,
and vitronectin) produced by human fibroblasts was performed by an in situ
ELISA. Human fibroblasts were plated in a 6-multiwell plate at a density of
5000 cells/well and analyzed after 72 h of culture. Proteins were fixed by
acetone/methanol (v/v), for 10 min at 22˚C, incubated in 0.5% PBS/BSA
and 0.2% Tween 20 for 30 min at 22˚C to minimize aspecific binding sites,
and washed in PBS. Mouse anti-collagen type I (2 mg/ml), anti-fibronectin
(2 mg/ml), and anti-vitronectin (2 mg/ml) were added for 1 h at 22˚C. After
three washes in PBS, plates were incubated (30 min at 22˚C) with HRP
anti-mouse IgG. After additional washes in PBS, the substrate was added
(1 mg/ml OFD, 0.1 mol/l citrate buffer [pH 5], and 0.006% H2O2), and
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plates were incubated for 30 min at 37˚C in the dark. The reaction was then
stopped by 1 N H2SO4, and the absorbance was read at 450 nm by
a spectrophotometer. Plates without cells and plates coated with purified
ECM components at different concentrations were used as controls.
Coimmunoprecipitation
BJ fibroblasts (5 3 106 cells/sample) were plated in 100-mm dishes for
24 h. Cells were lysed in radioimmunoprecipitation assay buffer supple-
mented with a mixture of proteases and phosphatases inhibitors and in-
cubated with mouse nonimmune serum (Jackson ImmunoResearch
Laboratories, Suffolk, UK) and 10% protein A-conjugated Sepharose (GE
Healthcare, Milan, Italy) for 2 h at 4˚C. After centrifugation, the super-
natants were incubated with 2 mg/ml of the R4 monoclonal anti-uPAR
Ab, provided by Dr. G. Hoyer-Hansen (Finsen Laboratory, Copenhagen,
Denmark), or with nonimmune mouse Igs for 2 h at 4˚C and then with 10%
protein A–Sepharose for 30 min at room temperature. The immunoprecip-
itates were washed in radioimmunoprecipitation assay buffer, subjected to
10% SDS-PAGE, and analyzed by Western blot analysis using a polyclonal
Ab directed against FPR1.
Determination of ROS
Intracellular ROS generation by adherent cells in a 6-well plate, after
loading cells with DCHF-DA, was measured by flow cytometry (FACS-
Calibur) as described previously (36). The esterified form of DCHF-DA
can permeate cell membranes before being deacetylated by intracellular
esterases. The resulting compound, dichlorodihydrofluorescein, reacts with
ROS, producing an oxidized fluorescent compound, dichlorofluorescein,
which can be detected by flow cytometry at a wavelength of 520 nm (FL1).
Cell monolayers were treated with medium alone, ATF-uPA (1028 M),
uPAR84–95 (10
29 M), WKYMVm peptide (1029 M), or H2O2 (1 mM), as
a positive control, for 30 min at 37˚C in a humidified 5% CO2 incubator.
Cells were then washed twice, and 5 mM DCHF-DAwas added for 30 min
in the dark at 37˚C. After incubation, cells were washed, trypsinized for
immediate analysis, and resuspended in PBS. A total of 104 events were
acquired for each sample in all cytofluorimetric analysis, and intracellular
ROS formation was detected as a result of the oxidation of DCHF. Results
are expressed as percentage of increase of mean fluorescence intensity in
respect to untreated cells.
Histology and immunohistochemistry
After clinical evaluation, a 3-mm skin punch was taken from the most
representative area of each patient affected by SSc and from 10 normal
subjects as a control. Each specimen was fixed in 10% buffered formalin,
embedded in paraffin, and serial sectioned (4-mm-thick sections). One
section for each case was stained with H&E and the others stained by
immunohistochemistry (labeled streptavidin biotin standard technique)
with anti-FPR1 Ab (1 mg/ml), anti-FPR2 Ab (10 mg/ml), and anti-FPR3
Ab (8 mg/ml). Cells showing a definite black staining confined to the
nucleus or cytoplasm were judged positive for FPRs 1, 2, and 3. All
slides were examined in a double-blinded fashion by two investigators
(M. Mascolo and S. Staibano), and the final staining for each case was
expressed as the percentage of positive cells among the total number of
counted cells (at least five high-power representative fields).
Statistical analysis
All the experiments were performed at least in triplicate. The results are
expressed as mean6 SEM. Values from groups were compared using a paired
Student t test (37). Differences were considered significant when p , 0.05.
Results
Expression of FPR1, FPR2, and FPR3 in human fibroblast
cells
We checked the specificity of each primer set on RNAs of KG-1
(human myeloid cell line), K-562 (human myelogenous leuke-
mia cell line), and U-937 (human leukemic monocyte lymphoma
cell line) cells. Fig. 1A shows that KG-1 expressed mRNA only for
FPR1 (38) and K-562 expressed mRNA only for FPR3, whereas
U-937 expressed mRNA both for FPR2 and FPR3 (13).
We examined FPRs expression in skin fibroblasts from 10
normal subjects and 10 SSc patients. The analysis of total RNA by
RT-PCR showed expression of all three FPRs (Fig. 1B). The three
receptors resulted upregulated in SSc fibroblasts as compared with
normal fibroblasts, with a significant increase for FPR2 and FPR3
(fold increase SSc versus normal fibroblasts: FPR1 2.6; FPR2
5.17; and FPR3 6.08) (Fig. 1B).
We then investigated FPR expression in normal and SSc
fibroblasts at a protein level. Western blot analysis with specific
Abs demonstrated that fibroblasts synthesize all the three FPRs
(Fig. 1C). Unexpectedly, we observed a different pattern of in-
crease of FPR protein expression as compared with mRNA levels.
Indeed, FPR1 and FPR3 expression increased in SSc fibroblasts as
compared with normal fibroblasts (fold increase SSc versus nor-
mal fibroblasts: FPR1 4.07; FPR3 1.3; p , 0.05), whereas FPR2
was not significantly upregulated (fold increase SSc versus normal
fibroblasts 1.02) (Fig. 1C).
These experiments demonstrate that both normal and SSc
fibroblasts express FPRs; moreover, SSc fibroblasts show an
overexpression as compared with normal cells. It is conceivable
that posttranscriptional mechanisms may regulate the expression of
these receptors in normal and SSc fibroblasts, causing a different
expression pattern at mRNA and protein level.
In vivo expression of FPRs
At histology (H&E staining, in Fig. 2 a representative case), all the
enrolled SSc cases (six limited cutaneous and four diffuse cutane-
ous) showed dermal fibrosis that characteristically involved the
subcutis, associated with chronic inflammatory infiltrate, mainly
localized at the interface between the deep dermis and subcutis
and around vessels (Fig. 2A–C), as compared with normal skin
(Fig. 2D). All the evaluated cases showed an increased positivity for
FPR1 (Fig. 2E–G), FPR2 (Fig. 2I–K), and FPR3 (Fig. 2M–O),
compared with that observed in normal skin (Fig. 2H, 2L, 2P), used
as a normal control. FPR1 was found diffusely positive in fibro-
blasts, endothelial cells, and lymphocytes. FPR2 was expressed in
several but not all fibroblasts, whereas FPR3 was seen extensively
expressed only in fibroblasts. These data are in agreement with the
in vitro observations, showing a lower expression of FPR2, at a
protein level, in SSc fibroblasts, compared with FPR1 and FPR3.
Effects of ATF-uPA, uPAR84–95, and WKYMVm on human skin
fibroblast chemotaxis and adhesion
Chemotaxis contributes to fibrosis by allowing recruitment of
fibroblasts, macrophages, and PBMCs to sites of tissue injury (8).
FPRs are chemotaxis receptors (11); therefore, we first tested the
capability of different FPRs agonists to induce directional mi-
gration of normal and sclerotic fibroblasts to investigate a possible
role of these receptors in some phases of the disease.
To this aim, we tested the capability of the uPAR-derived
chemotactic peptide uPAR84–95 and of the synthetic peptide
WKYMVm, which are FPRs agonists, to induce directional mi-
gration of normal and SSc fibroblasts. We also evaluated the effect
of the ATF of uPA (ATF-uPA), able to bind uPAR but devoid of
enzymatic activity, which promotes FPRs/uPAR cross-talk (23, 24).
Fig. 3A shows that normal fibroblasts efficiently migrated toward
ATF-uPA, uPAR84–95, and WKYMVm peptide (p , 0.001). SSc
fibroblasts showed a less vigorous migratory phenotype and a lower
response, as compared with normal fibroblasts, responding signifi-
cantly only to ATF-uPA and to the WKYMVm peptide (p , 0.05).
FPRs also regulate cell adhesion; indeed, their stimulation can
enhance mesenchymal stem cell adhesion to ECM protein–coated
surfaces (39), whereas their constitutive activation is involved in
cell de-adhesion (40). Thus, we tested the effects of FPRs agonists
on normal and SSc fibroblast adhesion to type I collagen. Stimu-
lation with ATF-uPA, uPAR84–95, and WKYMVm peptide induced
a significant detachment from collagen in normal fibroblasts,
whereas it did not exert any effect on SSc fibroblasts (Fig. 3B).
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These results suggest that migration mediated by FPRs is im-
paired in SSc fibroblasts, in particular in response to the chemo-
tactic uPAR88–95 peptide. Moreover, SSc fibroblasts are less
adhesive than normal fibroblasts to type I collagen, although not
significantly, and do not respond to FPRs agonists.
Effects of ATF-uPA, uPAR84–95, WKYMVm on human skin
fibroblast proliferation
It has been previously described that fibroblasts from idiopathic
pulmonary fibrosis display a less vigorous proliferation activity
(36). Thus, we analyzed the growth properties of normal and SSc
fibroblasts in the presence of 10% FBS. Interestingly, proliferation
of SSc fibroblasts was significantly lower as compared with nor-
mal cells at each point of the proliferation curve (Fig. 3C).
Because overexpression of FPR1 could confer a more invasive
and proliferative phenotype (41), the effect of different uPAR and
FPRs agonists on cell proliferation was investigated. Cells were
incubated with ATF-uPA, uPAR84–95, and WKYMVm peptide and
cell number was measured at 72 h (Fig. 3D). Proliferation of
normal fibroblasts significantly increased in response to all spe-
cific ligands; by contrast, only ATF-uPA was able to act in a sig-
nificant manner in SSc fibroblasts (Fig. 3D).
These results indicate that SSc fibroblasts proliferate less than
normal cells and, despite the overexpression of FPRs, poorly re-
spond to their ligands, except for ATF-uPA, that, indeed, only
indirectly can stimulate FPRs.
Effects of ATF-uPA, uPAR84–95, and WKYMVm on normal and
SSc skin fibroblast wound healing
During normal healing of skin, connective tissue is repaired ex-
clusively through the action of fibroblasts, which migrate into the
wound site (42). In in vitro wound healing assays, both normal and
FIGURE 1. (A) mRNA expression of FPRs in human leukemia cell lines. Total RNA was isolated and retrotrascribed from KG-1 cell line as a positive
control for FPR1 (lane 1), K-562 cell line as a positive control for FPR3 (lane 2), and U-937 cell line as a positive control for FPR2 and FPR3 (lane 3).
cDNAs were amplified by 40 PCR cycles in the presence of FPR1-, FPR2-, and FPR3-specific primers and GAPDH primers as loading control. (B) mRNA
expression of FPRs in normal and SSc fibroblasts. Total RNAwas isolated from skin fibroblasts derived from 10 normal subjects and 10 SSc patients; RNA
was retrotranscribed, and cDNAs were amplified by 40 PCR cycles in the presence of FPR1-, FPR2-, and FPR3-specific primers and GAPDH primers as
loading control. (B) is representative of the results obtained in three normal and three SSc subjects. Normalization using densitometric analysis of the FPR
expression in normal (white columns) and SSc (gray columns) fibroblasts show that SSc fibroblasts overexpress FPR2 and FPR3 as compared with normal
fibroblasts. Values are mean 6 SEM of 10 normal and 10 SSc subjects. (C) Western blot analysis of FPRs in normal and SSc fibroblasts. Skin fibroblasts
derived from 10 normal subjects and 10 SSc patients were lysed in Triton X-100, and 50 mg total protein was analyzed by Western blot with anti–FPR1-,
anti–FPR2-, and anti–FPR3-specific Abs and then with a-tubulin Abs for loading control. Normalization with a-tubulin using densitometric analysis of the
FPR protein levels show a significant increase of FPR1 and FPR3 in SSc fibroblasts (gray columns) as compared with normal fibroblasts (white columns).
Values are mean 6 SEM of 10 normal and 10 SSc subjects. *p , 0.05.
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SSc fibroblasts were able to close in a significant manner the
scratch at 8 and 24 h, compared with time 0, considered as
100% (Fig. 4A). However, the efficiency in wound healing by
SSc cells was higher at 24 h, compared with normal cells (p ,
0.05).
We then evaluated the effects of ATF-uPA, uPAR84–95, and
WKYMVm peptide in wound healing assays on normal and SSc
fibroblasts. The size of the gaps in the presence of the different
FPRs agonists was measured at different time points (0, 8, and
24 h) and compared with the gap size in the absence of agonists,
considered as 100%. Both in normal and SSc fibroblast, wound
healing efficiency was increased by all the stimuli at 24 h. At 8 h,
ATF-uPA, uPAR84–95, and WKYMVm peptide improved normal
fibroblasts wound healing, whereas only the WKYMVm pep-
tide exerted a significant effect on SSc fibroblasts (p , 0.05)
(Fig. 4B).
Thus, SSc fibroblasts show an increased basal motogenic activity
as compared with normal fibroblasts, as demonstrated previously
(43); however, except for the WKYMVm peptide, SSc fibroblast
response to FPRs agonists is strongly delayed.
Effects of ATF-uPA, uPAR84-95 and WKYMVm on normal and
SSc skin fibroblast ECM deposition
SSc is characterized by the overproduction of ECM proteins (44).
To investigate the possibility that deposition of ECM could be
regulated by FPR stimulation, we evaluated fibronectin, collagen
type I, and vitronectin secretion by in situ ELISAs in basal condition
and upon challenge with ATF-uPA, uPAR84–95, and WKYMVm, in
normal and SSc skin fibroblasts.
SSc fibroblasts showed only a slight increase in fibronectin
production in respect to normal fibroblasts; by contrast, collagen
type I and vitronectin deposition was significantly increased in SSc
fibroblasts (p , 0.05). Both cell types significantly increased
matrix deposition in response to FPRs stimulation (Fig. 4C).
Expression of myofibroblast associated markers on human skin
fibroblasts and their induction by FPR stimulation
In rheumatoid arthritis, fibroblast activation is characterized also
by the induction of the uPA pathway (45), even though we could
observe uPA increase only in localized SSc forms (29). uPA is
able to cleave uPAR (20, 22, 23). uPA-mediated uPAR cleavage
FIGURE 2. Histological expression of FPRs in skin biopsies. (A–C) Histologic appearance of a localized scleroderma. [H&E; original magnification350
(A), 3100 (B), and 3200 (C)]. (D) Histologic appearance of normal skin (H&E; original magnification 3100). (E–G) Immunostaining for FPR1 in a lo-
calized scleroderma. Overexpression of FPR1 was observed in fibroblasts, endothelial cells, and lymphocytes [original magnification 350 (E), 3100 (F),
and 3200 (G)]. (H) Immunostaining for FPR1 in normal skin. Weak expression of FPR1 was observed in fibroblasts, lymphocytes, and endothelial cells
(original magnification 3100). (I–K) Immunostaining for FPR2 in a localized scleroderma. Only a minority of fibroblasts resulted positive for FPR2
[original magnification 350 (I), 3100 (J), 3200 (K)]. (L) Immunostaining for FPR2 in normal breast skin in normal skin. Only two fibroblasts resulted
positive for FPR2 (original magnification, 3100). (M–O) Immunostaining for FPR3 in a localized scleroderma. Most fibroblasts show positivity for FPR3.
Lymphocytes and endothelial cells were negative [original magnification 350 (M), 3100 (N), 3200 (O)]. (P) Immunostaining for FPR3. Some fibroblasts
showed positivity for FPR3. Lymphocytes and endothelial cells were negative (original magnification 3100).
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results in the expression on the cell membrane of a truncated form of
the receptor, which can contain (DII-DIII-uPAR88–92) or not (DII-
DIII-uPAR) the chemotactic peptide (residues 88–92) able to interact
with FPRs and to regulate their signal (26). uPAR cleavage con-
tributes to the impaired angiogenesis observed in SSc patients (30).
Thus, we investigated DII-DIII-uPAR88–92 expression in normal and
SSc fibroblasts by Western blot analysis, using a specific Ab directed
against the Ser88-Arg-Ser-Arg-Tyr92 sequence (46). Fig. 5A shows
that SSc fibroblasts markedly overexpressed DII-DIII-uPAR88–92 (fold
increase SSc fibroblasts versus normal cells: 4.7; p , 0.05).
Many cultured cell types, including fibroblasts and endothelial
cells, do not synthesize in basal conditions, vitronectin, which
characterizes the myofibroblast phenotype (19), and directly binds
uPAR, inducing a specific cell signaling (18). We have therefore
investigated the expression of vitronectin in normal and SSc
fibroblasts by Western blot analysis. SSc fibroblasts significantly
overexpressed vitronectin, as compared with normal cells (fold
increase SSc fibroblasts versus normal cells: 4.26; p , 0.05),
supporting the hypothesis of a transition of SSc fibroblasts toward
the myofibroblast phenotype (Fig. 5B).
FIGURE 3. (A) Effects of ATF-uPA, uPAR84–95, and WKYMVm on normal and SSc skin fibroblast chemotaxis. Skin fibroblasts from normal subjects
and SSc patients were allowed to migrate in response to cell medium alone (white column) or ATF-uPA (1029 M) (light gray column), uPAR84–95 peptide
(1029 M) (dark gray column), or WKYMVm peptide (1028 M) (black column) for 6 h at 37˚C in a humidified (5% CO2) incubator. (B) Effects of ATF-uPA,
uPAR84–95, and WKYMVm on normal and SSc skin fibroblast adhesion. Skin fibroblasts from normal subjects and SSc patients were plated onto type I
collagen–coated wells and allowed to adhere in response to cell medium alone (white column) or ATF-uPA (1029 M) (light gray column), uPAR84–95
peptide (1029 M) (dark gray column), or WKYMVm peptide (1028 M) (black column) for 1 h at 37˚C in a humidified (5% CO2) incubator. Attached cells
were fixed and stained with crystal violet; the stain was eluted and the absorbance (OD) was determined by an ELISA reader at a wavelength of 540 nm. (C)
Proliferation of normal and SSc skin fibroblast. Normal and SSc skin fibroblasts were grown in 96-well plates for 1, 24, 48, 72, and 144 h in the presence of
10% FCS at 37˚C in a humidified (5% CO2) incubator. At the end of the incubation, 20 ml/well Cell Titer 96 reagent was added, and absorbance (OD) was
determined by ELISA reader at a wavelength of 490 nm. (D) Effects of ATF-uPA, uPAR84–95, and WKYMVm on normal and SSc skin fibroblast pro-
liferation. Normal and SSc skin fibroblasts were grown in 96-well plates for 72 h at 37˚C in a humidified (5% CO2) incubator in the presence of medium
alone (white column), ATF-uPA(1029 M) (light gray column), uPAR84–95 (10
29 M) (dark gray column), and WKYMVm peptide (1028 M) (black column)
at 37˚C in a humidified (5% CO2) incubator. At the end of the incubation, 20 ml/well Cell Titer 96 reagent was added, and absorbance (OD) was determined
by ELISA reader at a wavelength of 490 nm. Values are mean 6 SEM of six experiments. *p , 0.05, **p , 0.001.
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Then, we investigated the expression of a-SMA, a typical
marker of myofibroblast phenotype (8). Western blot analysis,
using a specific Ab against a-SMA, showed an increased ex-
pression in cell lysates from SSc fibroblasts as compared with
control (fold increase SSc fibroblasts vs normal cells: 2.97; p ,
0.05) (Fig. 5C).
To investigate whether this SSc cell phenotype was linked to the
activation of FPRs, we measured the expression of a-SMA in
control fibroblasts upon challenge with ATF-uPA, uPAR84–95, and
WKYMVm peptide. As shown in Fig. 5D, a-SMA expression was
strongly induced by specific ligands at 18 h in normal fibroblasts
(p , 0.05). No increase, except for ATF-uPA, was observed when
SSc fibroblasts were stimulated in the same conditions.
In SSc fibroblasts, the expression of avb5 and avb3 integrins is
upregulated and correlates with the transition of fibroblasts into
myofibroblasts (47, 48). uPAR, through its Ser88-Arg-Ser-Arg-
Tyr92 sequence, mediates FPR cross-talk with avb5 integrin, thus
inducing cell migration and cytoskeletal rearrangements (49).
Therefore, we also investigated avb5 expression and regulation by
FPR agonists in normal and SSc fibroblasts. Fig. 5D shows that
avb5 expression was strongly induced at 18 h in normal fibroblasts
by ATF-uPA and WKYMVm peptide (p , 0.05). When SSc
fibroblasts were stimulated in the same conditions, an increase was
observed with ATF-uPA (p , 0.05), and only WKYMVm peptide
exerted a stronger effect (p , 0.05).
Effects of ATF-uPA, uPAR84–95, and WKYMVm peptides on
human skin fibroblast ROS production
There are accumulating evidences suggesting a role of the oxidative
stress in the pathogenesis of SSc (50); indeed, it has been shown
FIGURE 4. (A) In vitro wound healing assay of normal and SSc fibroblasts. Migration was measured using a wound healing assay. Fibroblasts were
cultured on fibronectin until confluence, and a linear scrape was made across the cell layer. Migration of normal (Aa–Ac) and SSc (Ad–Af) fibroblasts was
monitored at time 0 [(Aa and Ad) white columns], 8 h [(Ab and Ae) light gray columns], and 24 h [(Ac and Af) black columns]. Original magnification310.
Three independent measurements of the scratch were performed; scratch size is expressed as a percentage of the original wound size at time 0, considered
as 100%. Values are mean 6 SEM of three experiments. (B) Effects of ATF-uPA, uPAR84–95, and WKYMVm on normal and SSc skin fibroblast on wound
healing. Skin fibroblasts from normal subjects and SSc patients were allowed to migrate in response to cell medium alone, ATF-uPA (1029 M), uPAR84–95
peptide (1029 M), or WKYMVm peptide (1028 M), for 0 h (white columns), 8 h (light gray columns), and 24 h (dark gray columns) at 37˚C in a humidified
(5% CO2) incubator. Scratch size is expressed as a percentage of the control wound obtained in the absence of agonist at the same time point (100%).
Values are mean 6 SEM of three experiments. (C) Effects of ATF-uPA, uPAR84–95, and WKYMVm on normal and SSc skin fibroblast ECM deposition.
Normal and SSc skin fibroblasts were grown in 6-multiwell plates in the presence of medium alone (white column), ATF-uPA (1029 M) (light gray
column), uPAR84–95 (10
29 M) (dark gray column), and WKYMVm peptide (1028 M) (black column) at 37˚C in a humidified (5% CO2) incubator for 72 h
at 37˚C in a humidified (5% CO2) incubator. Proteins were fixed by acetone/methanol and incubated with anti-fibronectin, anti-collagen type I, and anti-
vitronectin Abs for 1 h at 22˚C. Absorbance (OD) was determined by ELISA reader at a wavelength of 490 nm. Values are mean 6 SEM of six
experiments. *p , 0.05, **p , 0.001.
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that ROS contribute to the persistent fibrotic phenotype of SSc
fibroblasts (43) and that antioxidants, such as epigallocatechin-3-
gallate, can reduce ECM production, function, and activity of
dermal fibroblasts from SSc patients (44).
Several studies have described, among the various properties of
FPRs, the capability to generate ROS generation upon binding to
their specific ligands (50). Interestingly, SSc neutrophils may in-
duce local production of ROS upon fMLF stimulation in endo-
thelium (51).
Thus, we evaluated the effects of FPR activation on ROS release
in normal and SSc fibroblasts. Normal and SSc fibroblasts were
tested, by flow cytometry analysis, for the ability to induce ROS
generation. The basal level of fluorescence was determined in both
cell types after loading with DCHF-DA. DCHF-DA–loaded normal
and SSc fibroblasts did not show a different level of basal ROS
production (Fig. 6A). After cell stimulation with H2O2 (1 mM),
normal and SSc fibroblasts showed a similar, significant increase
in ROS production (Fig. 6B).
FIGURE 5. (A) Western blot analysis of DII-DIII-uPAR88–92 expression in normal and SSc skin fibroblasts. Normal (lanes 1–3) and SSc (lanes 4–6) skin
fibroblasts were lysed in Triton X-100, and 50 mg total protein was analyzed by Western blot with an anti–uPAR84–95-specific Ab; three representative cases
are shown. Densitometric analysis and normalization to a-tubulin of the DII-DIII-uPAR88–92 expression in normal (white column) and SSc fibroblasts (gray
column) are also shown. (B) Western blot analysis of vitronectin expression in normal and SSc skin fibroblasts. Normal (lanes 1–3) and SSc (lanes 4–6) skin
fibroblasts were lysed in Triton X-100, and 50 mg total protein was analyzed by Western blot with an anti–vitronectin-specific Ab; three representative cases
are shown. Densitometric analysis and normalization to a-tubulin of vitronectin expression in normal (white column) and SSc fibroblasts (gray column) are
also shown. (C) Western blot analysis of a-SMA and expression in normal and SSc skin fibroblasts. Normal (lanes 1–3) and SSc (lanes 4–6) skin fibroblasts
were lysed in Triton X-100, and 50 mg total protein was analyzed by Western blot with an anti–a-SMA-specific Ab. Three representative cases are shown.
Densitometric analysis and normalization to a-tubulin of the a-SMA expression in normal (white column) and SSc fibroblasts (gray column) are also
shown. (D) Effects of ATF-uPA, uPAR84–95, and WKYMVm in normal and SSc skin fibroblasts expression of a-SMA and avb5 integrin. Normal (lanes
1–4) and SSc (lanes 5–8) skin fibroblasts were treated with medium alone (lanes 1 and 5) or with ATF-uPA (1029 M) (lanes 2 and 6), uPAR84-95 (10
29 M)
(lanes 3 and 7), or WKYMVm peptide (1028 M) (lanes 4 and 8) for 18 h at 37˚C in a humidified (5% CO2) incubator. At the end of the incubation, cells
were lysed in Triton X-100, and 50 mg total protein was analyzed by Western blot with an anti–a-SMA and avb5 integrin–specific Ab; a representative case
of one normal and one SSc patient is shown. Densitometric analysis and normalization to a-tubulin of the a-SMA and avb5 integrin expression in normal
and SSc fibroblasts after treatment with medium alone (white column), ATF-uPA (1029 M) (light gray column), uPAR84–95 (10
29 M) (dark gray column), or
WKYMVm peptide (1028 M) (black column) are also shown. Values are mean 6 SEM of 10 normal and 10 SSc subjects. *p , 0.05.
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To investigate whether FPR stimulation may have a role in ROS
production, we evaluated ROS levels after stimulation with specific
agonists of uPAR/FPRs. The intracellular ROS levels were de-
termined after 30 min of stimulation with ATF-uPA, uPAR84–95,
and WKYMVm peptide (Fig. 6C) and compared with unstimu-
lated cells. As shown in Fig. 6C, normal fibroblasts responded in
a significant manner to all the three stimuli (p , 0.05), whereas in
SSc fibroblasts, only the pan-FPR agonist WKYMVm peptide
significantly induced ROS generation, thus suggesting that uPAR/
FPR cross-talk could be impaired in SSc fibroblasts.
Indeed, both intact (52) and cleaved DII-DIII-uPAR88–92, either
on the cell membrane (53) or in a soluble form (27), can interact
with FPRs in many cell types (20, 23). To investigate whether such
interaction could also occur in fibroblast cells, a pull-down ex-
periment was carried out in human skin fibroblasts from the BJ
cell line, constitutively expressing all FPRs and both forms of
uPAR (data not shown). In BJ cells, immunoprecipitation with
a monoclonal anti-uPAR Ab and Western blot analysis of the
immunoprecipitate with polyclonal anti-FPR1 Abs revealed a
band corresponding to FPR1 that was absent in the same lysate
FIGURE 6. (A) Intracellular oxidation in normal and SSc fibroblasts in basal conditions. Normal (n = 10, white column) and SSc (n = 10, gray column)
skin fibroblasts were plated in a 6-well plate. Cells were untreated or treated with H2O2 (1 mM) for 30 min at 37˚C in the dark. At the end of incubation,
cells were washed with PBS and loaded with DCHF-DA (5 mM) for 30 min; then, ROS release was measured by flow cytometry at a wavelength of 520 nm
(FL1). Results are expressed as percentage of increase of mean fluorescence intensity DCHF-DA–loaded cells, as compared with DCHF-DA–unloaded
cells. (B) Normal (n = 10, white column) and SSc (n = 10, gray column) skin fibroblasts were plated in a 6-well plate. Cells were untreated or treated with
H2O2 (1 mM) for 30 min at 37˚C in the dark. At the end of incubation, cells were washed with PBS and loaded with DCHF-DA (5 mM) for 30 min; then,
ROS release was measured by flow cytometry at a wavelength of 520 nm (FL1). Results are expressed as percentage of increase of mean fluorescence
intensity of H2O2-stimulated over H2O2-unstimulated cells. (C) Effects of ATF-uPA, uPAR84–95, and WKYMVm on ROS production in normal and SSc
skin fibroblasts. Normal and SSc fibroblasts were treated with medium alone (white column), ATF-uPA (1029 M) (light gray column), uPAR84–95 (10
29 M)
(dark gray column), and WKYMVm peptide (1028 M) (black column) for 30 min at 37˚C in a humidified 5% CO2 incubator. Cells were then washed twice,
and 5 mM DCHF-DAwas added for 30 min in the dark at 37˚C. At the end of the incubation, cells were washed, trypsinized, and resuspended in PBS for
flow cytofluorimetric analysis. A total of 104 events were acquired for each sample in all cytofluorimetric analysis, and intracellular ROS formation was
detected as a result of the oxidation of DCHF. DCHF-DA–loaded H2O2-unstimulated cells were considered the 100% of the dichlorofluorescein (DCF)
fluorescence. *p , 0.05. (D) uPAR coimmunoprecipitation with FPR1. BJ cell lysates were immunoprecipitated with the R4 anti-uPAR mAb (lane 2) or
with nonimmune serum (lane 1). The immunoprecipitated samples were electrophoresed on 10% SDS-PAGE and analyzed by Western blot analysis with an
anti-FPR1 Ab. Nonimmunoprecipitated cell lysates were subjected to Western blot analysis with the anti-FPR1 Ab (lane 3) as a loading control.
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immunoprecipitated with nonimmune Igs. As a control, a corre-
sponding band was evidenced in BJ total cell lysates subjected to
Western blot analysis with anti-FPR1 Abs (Fig. 6C). Therefore,
a structural interaction between uPAR and FPR1 can occur in the
fibroblast cell type and exert functional effects.
Discussion
The importance of the FPRs in different inflammatory conditions
and their involvement in innate immune responses is well estab-
lished (54). However, their involvement in SSc pathogenesis has
never been investigated. To our knowledge, our data demonstrate
for the first time both in vivo and in vitro that human skin fibro-
blasts express FPRs and that SSc fibroblasts ovreexpress FPR1,
FPR2, and FPR3 (Fig. 1B, 1C). FPRs could be involved in the
pathogenesis of SSc through different mechanisms, including
the interaction with the uPA/uPAR system, as previously demon-
strated in epithelial cells (26). Adhesion, proliferation, and che-
motaxis assays showed that ligands of uPAR and FPRs, including
the uPAR84–95 peptide, exerted a significant effect on normal skin
fibroblasts (Fig. 3). Despite the overexpression of FPRs, SSc
fibroblasts were less responsive to their ligands, except for ATF-
uPA, which exerted the same proliferative effect as in normal
fibroblasts.
Fibroblasts isolated from clinically affected, but not unaffected,
areas of SSc patients are characterized by elevated adhesion to and
contraction of ECM (47). Differently from bronchial human
fibroblasts (55), we found that dermal fibroblasts from SSc were
not more adherent to type I collagen. However, their adhesion was
insensitive to FPR activation, responsible for both deadhesion and
proadhesion activity in different cell types (39, 40).
These results suggest that FPRs are less functional in SSc
fibroblasts in respect to normal fibroblasts. Indeed, FPRs can be
inactivated and/or desensitized by several mechanisms, depending
on ligand engagement, activation of other chemotaxis receptors,
internalization, or phosphorylation (11). In the presence of inactive
FPRs, ATF-uPA is less efficient in inducing cell migration in SSc
fibroblasts, but it is still able to stimulate cell proliferation to the
same extent than normal fibroblasts, probably by activating other
signaling partners, such as, for instance, integrins (52). Fibroblasts
from lesional areas of SSc possess a motogenic phenotype and
increased ability to produce type I collagen (56). Accordingly, we
showed that SSc fibroblasts migrated faster in wound healing
assays and secreted more ECM proteins than normal cells (Fig. 4).
Moreover, incubation with FPRs agonists increased the rate of
wound healing and ECM deposition in both normal and SSc
fibroblasts.
Interestingly, previous studies have evidenced that retaining full-
length uPAR is essential for regulating myofibroblast differentia-
tion and that the cleavage/inactivation of uPAR is a crucial step in
the fibroblast-to-myofibroblast transition (57). This hypothesis has
been supported by the observation that uPAR deletion induces,
in a murine model, pulmonary fibrosis and peripheral micro-
vasculopathy (58). On this basis, we also investigated whether SSc
fibroblasts, which show an increased membrane expression of
cleaved uPAR, exhibited characteristics suggesting a myofibro-
blast transition. Indeed, we demonstrated increased vitronectin
production from SSc fibroblasts, which is associated to fibrosis
and myofibroblast phenotype (25).
Myofibroblasts also show increased a-SMA expression, which
represents the key feature of cellular response to injury and of an
uncontrolled activated phenotype. Indeed, we observed increased
expression of a-SMA in SSc fibroblasts and showed that uPAR/
FPRs stimulation and cross-talk was able to induce, in normal
fibroblasts, an increased expression of a-SMA. Thus, we could
hypothesize that FPRs/uPAR could be involved in the arising of
myofibroblast features. However, a-SMA overexpressing SSc
fibroblasts failed to still respond to FPR agonists and increased
their a-SMA production only in response to ATF-mediated uPAR
stimulation. We can suggest that, as in SSc fibroblasts prolifera-
tion, FPRs and their cross-talk with uPAR are inactivated, but
uPAR is still active, most probably through the engagement of
different membrane partners. Indeed, in corneal fibroblasts, uPA
treatment is able to induce myofibroblast differentiation by acti-
vating avb3 and avb5 integrins and promoting their binding to
vitronectin, which is overexpressed in corneal fibroblasts (59) as
well as in SSc fibroblasts (Fig. 3B).
avb3 integrin and avb5 are upregulated in SSc fibroblasts (60,
61) and contribute to the pathogenesis of fibrotic disorders by
promoting cell migration, vitronectin endocytosis, and TGF-b
autocrine signaling (47). avb5 expression can be upregulated by
uPAR activation, thus increasing cell adhesion and migration (62).
We documented that uPAR engagement by ATF-uPA was able to
increase avb5 expression also in normal and in SSc fibroblasts; in
addition, FPR stimulation determined a stronger effect in both cell
types (Fig. 4D).
Integrin-mediated signals contribute to the fibrotic phenotype of
SSc fibroblasts by the same molecular mechanisms that operate
downstream ROS (43). Indeed, several years ago, many groups
(10, 43, 44, 63) suggested that the pathogenesis of scleroderma
was linked to the generation of a large excess of ROS. The
scleroderma phenotype at the cellular level is characterized by
oxidative stress associated with the accumulation of large amounts
of ROS in fibroblasts. ROS are key cell transducers of fibroblast
proliferation and collagen-gene expression. Furthermore, several
studies in animal models of scleroderma have confirmed the rel-
evance of oxidative stress in the pathogenesis of the fibrotic
processes (57). It has been previously demonstrated that uPA
activation is able to induce, in a model of arterial injury, ROS
generation (64). Interestingly, Barnes et al. (65) showed that
neutrophil stimulation with a specific FPR agonist resulted in in-
creased ROS generation in SSc neutrophils. To this regard, we
finally analyzed the effects of uPAR/FPRs stimulation on fibro-
blasts ROS production, showing that normal fibroblasts signifi-
cantly respond to all the agonists. On the contrary, only the
WKYMVm peptide seems to be a potent stimulus for SSc fibro-
blasts.
In conclusion, to our knowledge, our data show, for the first
time, that FPRs and their cross-talk with the uPA/uPAR system are
involved in the activation of normal fibroblasts proliferation, mi-
gration, and induction of a myofibroblast phenotype through ROS
generation, matrix deposition, and a-SMA overexpression. This
supports the hypothesis that the SSc progressive fibrosis could be
linked to aberrant activation of FPRs signaling. We indeed suggest
that, although in normal fibroblasts a cross-talk between the FPRs
and uPAR occurs, as demonstrated by coimmunoprecipitation
experiments and by significant response to the uPAR88–95 peptide
in the adhesion, migration, and proliferation assays, in SSc
fibroblasts a condition of inactivation probably contribute to the
reduced response observed in vitro (Fig. 3). This desensitization/
inactivation could be due to the increased membrane expression of
uPAR88–92 observed in vitro in SSc fibroblasts. Moreover, in SSc
fibroblasts, uPAR signaling is still active in inducing a-SMA
production, whereas FPRs are engaged preferentially in ROS
generation.
SSc is a heterogeneous disease in which vascular, inflammatory/
autoimmune, and fibrotic processes occur simultaneously and
contribute to organ damage. Early recognition and treatment of
symptoms and life-threatening complications are therefore crucial
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for SSc patient clinical evolution (66). The capacity of FPRs,
through the interaction with the uPA/uPAR system, to trigger the
transformation of fibroblasts to myofibroblast and to coordinate
proliferation and cell migration makes them a potential novel
therapeutic target in the treatment of early SSc.
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